Why Is Sportradar Stock Going Up?
Sportradar (NASDAQ:SRAD) should be on your radar for a stock…
Sell
34
RCEL Quote, Financials, Valuation and Earnings
Last price:
$8.94
Seasonality move
:
5.78%
Day range:
$8.85 - $9.18
52-week range:
$7.51 - $16.65
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
3.60x
P/B ratio:
52.32x
Volume:
249.8K
Avg. volume:
233.9K
1-year change:
-44.64%
Market cap:
$235.4M
Revenue:
$64.3M
EPS (TTM):
-$2.39
Analysts' Opinion
-
Consensus RatingAVITA Medical has received a consensus rating of Buy. The company's average rating is a Buy based on 4 Buy ratings, 2 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $16.23, AVITA Medical has an estimated upside of 81.74% from its current price of $8.93.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $11.04 representing 100% downside risk from its current price of $8.93.
Fair Value
-
According to the consensus of 6 analysts, AVITA Medical has 81.74% upside to fair value with a price target of $16.23 per share.
RCEL vs. S&P 500
-
Over the past 5 trading days, AVITA Medical has overperformed the S&P 500 by 3.92% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
AVITA Medical does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
AVITA Medical has grown year-over-year revenues for 9 quarters straight. In the most recent quarter AVITA Medical reported revenues of $18.4M.
Earnings Growth
-
AVITA Medical has grown year-over-year earnings for 0 quarters straight. In the most recent quarter AVITA Medical reported earnings per share of -$0.44.
Enterprise value:
241.7M
EV / Invested capital:
5.17x
Price / LTM sales:
3.60x
EV / EBIT:
--
EV / Revenue:
3.76x
PEG ratio (5yr expected):
-0.05x
EV / Free cash flow:
-4.15x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$55.2M
Return On Assets:
-67.57%
Net Income Margin (TTM):
-96.26%
Return On Equity:
-252.91%
Return On Invested Capital:
-93.94%
Operating Margin:
-54.1%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $34.4M | $50.1M | $64.3M | $14.2M | $18.4M | |
| Gross Profit | $28.4M | $42.4M | $55.2M | $12.4M | $16.1M | |
| Operating Income | -$27.5M | -$42.7M | -$56.6M | -$12.3M | -$10M | |
| EBITDA | -$26M | -$33.5M | -$55.3M | -$5.7M | -$9.9M | |
| Diluted EPS | -$1.07 | -$1.40 | -$2.39 | -$0.28 | -$0.44 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $65.5M | -- | $87.5M | $104M | $57M | |
| Total Assets | $69.3M | -- | $98.3M | $111.6M | $79.7M | |
| Current Liabilities | $7.9M | -- | $10.7M | $13.2M | $20.2M | |
| Total Liabilities | $9.7M | -- | $13.5M | $62.6M | $75.2M | |
| Total Equity | $59.6M | -- | $84.7M | $49.1M | $4.5M | |
| Total Debt | -- | -- | -- | $39.8M | $42.2M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$19.1M | -$38M | -$48.9M | -$10.9M | -$8.1M | |
| Cash From Investing | -$19.3M | $1.6M | $37.4M | -$57.3M | $2.5M | |
| Cash From Financing | $900K | $40.4M | $3.5M | $39.4M | $1M | |
| Free Cash Flow | -$19.6M | -$39.5M | -$58.3M | -$11.2M | -$9.7M | |
RCEL
Sector
Market Cap
$235.4M
$39.2M
Price % of 52-Week High
53.64%
45.93%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.81%
1-Year Price Total Return
-44.64%
-38.63%
Beta (5-Year)
1.575
0.774
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$9.01
200-day SMA
Sell
Level
$10.08
Bollinger Bands (100)
Sell
Level
8.93 - 12.59
Chaikin Money Flow
Sell
Level
-9.2M
20-day SMA
Sell
Level
$8.99
Relative Strength Index (RSI14)
Sell
Level
48.10
ADX Line
Buy
Level
14.24
Williams %R
Neutral
Level
-50.2857
50-day SMA
Sell
Level
$9.26
MACD (12, 26)
Sell
Level
-0.11
25-day Aroon Oscillator
Sell
Level
-56
On Balance Volume
Neutral
Level
7.5M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-4.604)
Sell
CA Score
(Annual)
Level (-3.8711)
Sell
Beneish M-Score
(Annual)
Level (-1.8089)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (6.5206)
Buy
Piotroski F Score
(Annual)
Level (4)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (6)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult patients in the US with paediatric clinical trials and expanded indications in soft-tissue reconstruction and vitiligo underway. It is currently in roll-out across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.
Stock Forecast FAQ
In the current month, RCEL has received 4 Buy ratings 2 Hold ratings, and 0 Sell ratings. The RCEL average analyst price target in the past 3 months is $16.23.
-
Where Will AVITA Medical Stock Be In 1 Year?
According to analysts, the consensus estimate is that AVITA Medical share price will rise to $16.23 per share over the next 12 months.
-
What Do Analysts Say About AVITA Medical?
Analysts are divided on their view about AVITA Medical share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that AVITA Medical is a Sell and believe this share price will drop from its current level to $11.04.
-
What Is AVITA Medical's Price Target?
The price target for AVITA Medical over the next 1-year time period is forecast to be $16.23 according to 6 Wall Street analysts, 4 of them rate the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is RCEL A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for AVITA Medical is a Buy. 4 of 6 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of RCEL?
You can purchase shares of AVITA Medical via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase AVITA Medical shares.
-
What Is The AVITA Medical Share Price Today?
AVITA Medical was last trading at $8.94 per share. This represents the most recent stock quote for AVITA Medical. Yesterday, AVITA Medical closed at $8.93 per share.
-
How To Buy AVITA Medical Stock Online?
In order to purchase AVITA Medical stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Roblox Stock a Buy, Sell or Hold?
Gaming company Roblox (NYSE:RBLX) operates a massive platform that allows…
Is Shopify a Millionaire Maker?
Shopify (NYSE:SHOP) is an eCommerce platform, business services provider and…
Stock Ideas
Buy
55
Is AAPL Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 36x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Buy
51
Is NVDA Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 40x
Alerts
Sell
50
RGC alert for Mar 22
Regencell Bioscience Holdings [RGC] is up 27.82% over the past day.
Sell
36
VMI alert for Mar 22
Valmont Industries [VMI] is down 12.54% over the past day.
Buy
61
ALNY alert for Mar 22
Alnylam Pharmaceuticals [ALNY] is up 11.7% over the past day.
